RxDoctor Payments Data

Eric Oligino, MD

Cardiovascular Disease · Hartford, CTNPI 1962605345

Payments from drug & device makers

$10,514in general payments, 2019–2025

Across 67 payments — averaging $156.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Johnson & Johnson$364
  • E.r. Squibb & Sons, L.L.C.$140
  • Novo Nordisk$116
  • Boehringer Ingelheim$96
  • Baxter Healthcare$89
  • plus $461 from 11 others

What the payments were for

  • Food & beverage$1,02781%
  • Education$937%
  • Other$14612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,514 in reported general payments places this provider in the 80th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$182,872
Medicare patients
1,469
Services billed
2,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban312$443,103
EntrestoSacubitril/Valsartan66$99,475
Repatha SureclickEvolocumab93$75,751
XareltoRivaroxaban48$75,732
JardianceEmpagliflozin53$63,487
BrilintaTicagrelor20$24,916
Metoprolol Succinate497$6,992
Nebivolol Hcl71$4,641
Rosuvastatin Calcium407$4,410
Ezetimibe145$2,941
Olmesartan Medoxomil155$2,540
Atorvastatin Calcium363$2,419
Amlodipine Besylate299$1,755
Losartan Potassium229$1,579
Torsemide100$1,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$40$99,47566 claims
Johnson & JohnsonXarelto$364$75,73248 claims
Boehringer IngelheimJardiance$96$63,48753 claims
AstraZenecaBrilinta$55$24,91620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →